Overview

Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

Status:
Completed
Trial end date:
2017-02-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI-546 in Japanese SLE patients.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
MedImmune LLC
Treatments:
Antibodies, Monoclonal